Primopex 25 mg 50 Tablets Sixpex USA
$125.00
Product Short Description
Primopex 25 mg 50 Tablets Sixpex USA delivers methenolone acetate (C22H32O3), the 1-methylated DHT-derived anabolic steroid, at balanced oral 25 mg potency matching institutional performance specifications. Domestic production eliminates customs exposure serving DEA Schedule III compliant channels exclusively.
Product Overview
Sixpex USA’s Primopex 25 mg presents methenolone acetate, exhibiting mild anabolic properties (~88:44-57 ratio) with acetate ester enabling oral bioavailability, in scored tablets for institutional catalogs. The 50-tablet tamper-evident configuration supports CIII-compliant inventory management across encrypted specialist platforms requiring precise potency declaration essential for DEA-regulated workflows.
U.S. domestic manufacturing maintains pharmaceutical-grade specifications distinguishing legitimate Schedule III supply from underground conversions prevalent in non-verified markets. This moderate dosage serves advanced resellers managing controlled substance inventories rather than high-potency or general supplement crossover.
Primopex targets verified CIII ecosystems emphasizing commercial positioning without protocols or claims.
Brand & Manufacturer Information
Sixpex USA produces Schedule III anabolics through domestic facilities serving institutional performance distribution requiring controlled substance compliance. Primopex maintains catalog continuity alongside Sixpex Oxapex/Halopex with consistent 25 mg tablet morphology authenticating legitimate institutional supply.
Domestic warehousing supports DEA Form 222 record-keeping confirming methenolone acetate identity/potency across encrypted platforms.
Active Compound Information
Contains methenolone acetate (1-methyl-17β-acetoxy-5α-androst-1-en-3-one), 1-methylated DHT derivative featuring low hepatotoxicity characteristic of non-17α-alkylated oral steroids with short ~4-6 hour acetate ester half-life. DEA Schedule III (21 CFR 1308.13) classification despite milder profile versus alkylated alternatives.
25 mg strength positions institutional-grade oral Primobolan maintaining DHT backbone without aromatization. WADA S1a prohibited globally.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Primopex 25 mg 50 Tablets Sixpex USA |
| Active Compound | Methenolone acetate (C22H32O3) |
| Strength | 25 mg per tablet |
| Quantity | 50 tablets per bottle |
| Form | Oral scored tablets |
| Category | DEA Schedule III controlled substance |
| Packaging | Tamper-evident HDPE bottle |
| Label Elements | 25 mg declaration, batch code, CIII warnings |
Quality Control & Testing Standards
25 mg methenolone acetate requires potency assay, acetate ester verification, and dissolution profiling confirming pharmaceutical-grade uniformity. Sixpex batch documentation verifies C22H32O3 identity and Schedule III-compliant excipients distinguishing legitimate production.
50-tablet institutional bottling prevents diversion matching DEA protocols; domestic warehousing maintains stability.
Intended Use & Market Positioning
Serves CIII-licensed institutional researchers managing DEA Schedule III oral anabolic inventories exclusively. 25 mg/50-tab excludes crossover within premium domestic catalogs. No protocols represented.
Legal & Regulatory Disclaimer
Methenolone acetate constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act. Buyer assumes Form 222 compliance; zero medical claims provided.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.